FRIEDRICH, Md., September 30, 2021 / PRNewswire-PRWeb / – Mr. Michael Mesa, CEO of Mesa Green Pharma (MGP), said that “Company representatives will be meeting with the FDA’s Center for Veterinary Medicine (CVM) at September 9, 2021to discuss the company’s development program for K9MGP. “MGP is developing K9MGP as a treatment to end active generalized seizures in dogs that can be administered by the pet owner at home, the only FDA-approved product for the treatment of active generalized seizures in dogs. K9MGP will address a significant unmet canine health care need by providing treatment as soon as possible after a seizure has started to minimize brain damage in the dog and improve the quality of life for the pet and its owner alike. “
At the meeting, MGP presented data from pilot studies that were carried out on University of Minnesota in association with the Mayo Clinic, which has shown that when injected intramuscularly through a prototype auto-injector system, K9MGP can rapidly reach the canine brain and rapidly reach therapeutic blood levels. MGP believes the pilot study will help further develop the innovative approach to addressing unmet seizure treatment needs. These data are used by the December 2021 American Epilepsy Society meeting.
Discussions with CVM during this meeting give confidence to MGP’s plans in 1. Once the INAD is open, MGP will discuss details of the target animal safety study and the efficacy study with CVM before submitting an application for an extended conditional license.
Mesa Green Pharmaceutical Company, a subsidiary of Mesa Science Associates Inc, is a veteran company with offices in the Frederick Innovation Technology Center (FITCI), located in Frederick MD. Inquiries about investment opportunities should be addressed to Michael Mesa at mike@mesagreenpharma.com.
Media contact
Michael Mesa, Mesa Green Pharma LLC, 240-778-8616, mike@mesagreenpharma.com
SOURCE Mesa Green Pharma LLC
